Medicare Enrolled

Dr. Edward Marcus, M.D.

Ophthalmology · New York, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
140 E 80TH ST, New York, NY 10075
2127722500
Registered in NPPES since 2008
NPI: 1841451937 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Marcus from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Marcus? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Marcus

Dr. Edward Marcus is an ophthalmology specialist in New York, NY, with 18 years of NPI registration. Based on federal Medicare data, Dr. Marcus performed 32,549 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Marcus received a total of $124,482 from 34 pharmaceutical and/or device companies across 1046 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Marcus is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years of NPI registration ▲ Top 1% volume in NY $124,482 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
32,549
Medicare services
Top 1% in NY for ophthalmology
Not available
Unique patients (not deduplicated)
$120
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Eye injection (Vabysmo/faricimab)
An injection of faricimab-svoa, a medication administered in 0.1 mg doses.
17,286 $29 $107
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
3,768 $35 $133
Eye injection for retinal disease
A procedure involving the administration of medication directly into the eye.
2,009 $107 $990
Aflibercept eye injection (Eylea) 1,878 $671 $1,481
Pegcetacoplan intravitreal injection, 1 mg
An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram.
1,470 $111 $184
Retinal laser destruction of growth
A laser procedure used to destroy abnormal growths in the retina.
1,050 $465 $1,971
Retinal angiography with dye injection
This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body.
895 $128 $380
Eye exam, established patient, focused
A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom.
856 $78 $183
Dexamethasone intravitreal implant injection
An injection of a dexamethasone implant placed inside the eye. This procedure delivers medication directly into the vitreous cavity of the eye.
819 $153 $393
Comprehensive eye exam, established patient
A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider.
587 $99 $312
Injection, brolucizumab-dbll, 1 mg 564 $247 $500
Fluocinolone acetonide intravitreal implant
An implant containing fluocinolone acetonide is placed inside the eye to deliver medication directly to the vitreous.
418 $384 $579
Bevacizumab injection, 10 mg
Administration of a 10 mg dose of bevacizumab medication via injection.
263 $50 $150
Unclassified drug
A medication that does not fit into standard HCPCS or CPT classification categories.
238 $1,502 $2,666
Ranibizumab-nuna biosimilar injection, 0.1 mg
An injection of the biosimilar medication ranibizumab-nuna (Byooviz) at a dose of 0.1 mg.
118 $168 $292
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
115 $83 $220
Retinal photography (fundus photo)
This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures.
102 $28 $150
Vitreous removal between lens and retina
This procedure involves the removal of the vitreous fluid located between the lens and the retina of the eye.
47 $821 $2,709
Comprehensive eye exam, new patient
A comprehensive examination of the visual system performed for a new patient.
41 $124 $272
Complex detached retina repair with eye fluid drainage
A surgical procedure to repair a detached retina and drain fluid located between the lens and the retina.
13 $1,220 $6,000
Removal of retinal membrane
A surgical procedure to remove a membrane from the surface of the retina.
12 $984 $8,000
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.

Industry Payment Transparency

Open Payments through 2024 ↗
$124,482
Total received (2018-2024)
Avg $17,783/year across 7 years
Top 2% in NY for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
1,046
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$40,447
2023
$16,550
2022
$18,634
2021
$16,148
2020
$14,333
2019
$12,406
2018
$5,963

Payments by company (2024)

Alimera Sciences, Inc.
$12,246
Astellas Pharma US Inc
$10,457
Regeneron Healthcare Solutions, Inc.
$6,381
Bausch & Lomb Americas Inc.
$5,824
Apellis Pharmaceuticals, Inc.
$2,781
Mallinckrodt Hospital Products Inc.
$535
Harrow Eye, LLC
$522
Sandoz Inc.
$499
ABBVIE INC.
$358
Genentech USA, Inc.
$261
ANI Pharmaceuticals, Inc.
$208
Dutch Ophthalmic, USA
$152
Biogen, Inc.
$82
Coherus Biosciences Inc.
$68
BIOTISSUE HOLDINGS INC.
$49
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Top 3 companies account for 71.9% of 2024 payments
All-time payments by company (2018-2024) ›
Alimera Sciences, Inc.
$32,987
Regeneron Healthcare Solutions, Inc.
$22,420
Astellas Pharma US Inc
$15,482
Mallinckrodt Hospital Products Inc.
$8,774
Bausch & Lomb Americas Inc.
$6,812
EyePoint Pharmaceuticals US, Inc.
$5,498
Allergan Inc.
$4,371
Allergan, Inc.
$3,761
Novartis Pharmaceuticals Corporation
$3,623
Mallinckrodt LLC
$3,505
Dutch Ophthalmic, USA
$3,412
Apellis Pharmaceuticals, Inc.
$3,404
Novartis Pharma AG
$2,925
NOVARTIS PHARMACEUTICALS CORPORATION
$2,601
Genentech USA, Inc.
$958
ABBVIE INC.
$835
Coherus Biosciences Inc.
$663
Harrow Eye, LLC
$522
Sandoz Inc.
$499
Mallinckrodt Enterprises LLC
$238
Biogen, Inc.
$228
ANI Pharmaceuticals, Inc.
$208
BioTissue Holdings, Inc.
$152
RxSight Inc
$131
Alcon Vision LLC
$120
BIOTISSUE HOLDINGS, INC.
$94
Horizon Therapeutics plc
$72
BIOTISSUE HOLDINGS INC.
$49
Oyster Point Pharma, Inc.
$38
Sun Pharmaceutical Industries Inc.
$31
Ocular Therapeutix, Inc.
$25
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Bausch & Lomb, a division of Bausch Health US, LLC
$16
NotalVision
$6
Top 3 companies account for 56.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ALPHAGAN P · BEOVU · BYOOVIZ · BromSite (bromfenac ophthalmic solution) 0.075% · CEQUA · Cequa · Cimerli · Clareon · DEXTENZA · DEXYCU · DURYSTA · EVA · EVA Ophthalmic Surgical System · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · ForeseeHome · HYDRUS Microstent · IHEEZO · ILUVIEN · Iluvien · Izervay · LUMIGAN · Lucentis · MIEBO · OZURDEX · PROKERA · PURIFIED CORTROPHIN GEL · RESTASIS MULTIDOSE · RXSIGHT CONTACT LENS · STELLARIS · SUSVIMO · Syfovre · TEPEZZA · TYRVAYA · VABYSMO · VEVYE · VUITY · VYZULTA · Vabysmo · XIIDRA · XIPERE · YUTIQ · combined machine
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for an ophthalmology specialist in New York?
Compare ophthalmologists in the New York area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologists nearby

Geographic Context

Ophthalmologists in nearby ZIP areas
1,398
County median income
$104,553
Nearest hospital to ZIP centroid (approximate)
LENOX HILL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Marcus is a mixed practice specialist, with above-average Medicare volume (top 1% in NY), with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Marcus experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Marcus performed 17,286 eye injection (vabysmo/faricimab) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Marcus receive payments from pharmaceutical companies?
Yes. Dr. Marcus received a total of $124,482 from 34 companies across 1,046 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Marcus's costs compare to other ophthalmologists in New York?
Dr. Marcus's average Medicare payment per service is $120. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Marcus) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →